Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive

por Gourley, Charlie
Publicado 2019

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge

por Symeonides, Stefan, Gourley, Charlie
Publicado 2015

Genetic and molecular changes in ovarian cancer

por Hollis, Robert L, Gourley, Charlie
Publicado 2016

Erratum to Genetic and molecular changes in ovarian cancer

por Hollis, Robert L, Gourley, Charlie
Publicado 2017

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

por Hollis, Robert L, Churchman, Michael, Gourley, Charlie
Publicado 2017

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin

por Morgan, Stephanie, Lopes, Federica, Gourley, Charlie, Anderson, Richard A., Spears, Norah
Publicado 2013

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer

por Langdon, Simon P., Herrington, C. Simon, Hollis, Robert L., Gourley, Charlie
Publicado 2020

Patients’ Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing

por Wright, Sarah, Porteous, Mary, Stirling, Diane, Lawton, Julia, Young, Oliver, Gourley, Charlie, Hallowell, Nina
Publicado 2018

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma

por Hollis, Robert L., Croy, Ian, Churchman, Michael, Bartos, Clare, Rye, Tzyvia, Gourley, Charlie, Herrington, C. Simon
Publicado 2022

Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ

por Song, Liang, McNeil, Ewan M., Ritchie, Ann-Marie, Astell, Katy R., Gourley, Charlie, Melton, David W.
Publicado 2017

Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models

por Langdon, Simon P., Kay, Charlene, Um, In Hwa, Dodds, Michael, Muir, Morwenna, Sellar, Grant, Kan, Julie, Gourley, Charlie, Harrison, David J.
Publicado 2019

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma

por Hollis, Robert L., Stanley, Barbara, Iida, Yasushi, Thomson, John, Churchman, Michael, Rye, Tzyvia, Mackean, Melanie, Nussey, Fiona, Gourley, Charlie, Herrington, C. Simon
Publicado 2019

Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?

por Barnes, Dominique, Mohammad, Nissreen, Hoang, Lien, Anglesio, Michael, Hollis, Robert L., Gourley, Charlie, Stuart, Heather C., Carey, Mark S., Stuart, Gavin C.E.
Publicado 2022

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

por Nicum, Shibani, Roberts, Corran, Boyle, Lucy, Kopijasz, Sylwia, Gourley, Charlie, Hall, Marcia, Montes, Ana, Poole, Christopher, Collins, Linda, Schuh, Anna, Dutton, Susan J
Publicado 2014

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells

por Gomez, Miriam K., Illuzzi, Giuditta, Colomer, Carlota, Churchman, Michael, Hollis, Robert L., O’Connor, Mark J., Gourley, Charlie, Leo, Elisabetta, Melton, David W.
Publicado 2020

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

por Xintaropoulou, Chrysi, Ward, Carol, Wise, Alan, Queckborner, Suzanna, Turnbull, Arran, Michie, Caroline O., Williams, Alistair R. W., Rye, Tzyvia, Gourley, Charlie, Langdon, Simon P.
Publicado 2018

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer

por Goh, Jeffrey C.H., Gourley, Charlie, Tan, David S P, Nogueira-Rodrigues, Angélica, Elghazaly, Hesham, Edy Pierre, Marc, Giornelli, Gonzalo, Kim, Byoung-Gie, Morales–Vasquez, Flavia, Tyulyandina, Alexandra
Publicado 2022

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

por Hollis, Robert L., Meynert, Alison M., Churchman, Michael, Rye, Tzyvia, Mackean, Melanie, Nussey, Fiona, Arends, Mark J., Sims, Andrew H., Semple, Colin A., Herrington, C. Simon, Gourley, Charlie
Publicado 2018

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse

por Hollis, Robert L., Carmichael, Juliet, Meynert, Alison M., Churchman, Michael, Hallas-Potts, Amelia, Rye, Tzyvia, MacKean, Melanie, Nussey, Fiona, Semple, Colin A., Herrington, C. Simon, Gourley, Charlie
Publicado 2019

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

por Roberts, Corran, Strauss, Victoria Y., Kopijasz, Sylwia, Gourley, Charlie, Hall, Marcia, Montes, Ana, Abraham, Jacinta, Clamp, Andrew, Kennedy, Richard, Banerjee, Susana, Folkes, Lisa K., Stratford, Michael, Nicum, Shibani
Publicado 2019